Biosimilar Names: Naming Rules & Brands Stocked in India
How biosimilar names are actually assigned under WHO's INN and biological qualifier framework, why traceability matters, and which India brands hospitals stock.
This piece covers how biosimilar naming actually works under WHO's framework, why India's own biosimilar market has grown a wide brand roster across several major molecule classes, and why precise naming and batch-level dispensing records matter more for hospital pharmacovigilance in this drug category than for standard generics. A pharmacy dispensing biosimilar names correctly is practising real pharmacovigilance discipline, not just paperwork.
Why does biosimilar naming need a different system than generic drug naming?
A generic small-molecule drug can be confirmed chemically identical to its originator, so one INN safely covers every manufacturer's version. A biosimilar is different: a biologically manufactured protein or antibody, highly similar to but not identical to its reference biologic. That structural difference is precisely why regulators require distinct traceability at the brand and batch level, rather than treating every biosimilar under one interchangeable name.
The World Health Organization's biosimilars access toolkit sets out this traceability principle directly: each biosimilar needs a unique brand name, the shared INN of the active substance, and a batch number recorded at dispensing, specifically so that any adverse event can be traced back to the exact manufactured lot, not just the general drug class.
What is WHO's "biological qualifier" proposal, and where does it stand?
WHO proposed a four-letter biological qualifier code, added after the shared INN, to give every biosimilar and its reference product a globally consistent identifier distinct from national brand names, aimed at avoiding a patchwork of different national naming schemes for the same underlying traceability problem. The intent was to standardise how prescribers, pharmacists and pharmacovigilance systems worldwide identify a specific biosimilar product regardless of brand name.
WHO has since paused formal rollout of the biological qualifier suffix, partly reflecting how the European Union's existing approach, brand name plus batch number without a qualifier suffix, has functioned adequately in practice. India's own regulatory approach currently follows the brand-name-plus-batch-number model rather than adopting a separate qualifier code.
Which biosimilar molecule classes have the widest brand rosters in India?
India's biosimilar market spans monoclonal antibodies, insulins and supportive-care biologics, with multiple domestic manufacturers holding approval for the same reference molecule. Trastuzumab and rituximab biosimilars, insulin glargine biosimilars, and biosimilars of filgrastim, pegfilgrastim, bevacizumab and darbepoetin alfa each have several approved Indian manufacturer brands competing under distinct names sharing the same underlying INN.
This breadth is a direct consequence of India's comparatively larger biosimilar approval pipeline relative to some other major markets, a pattern documented in published regulatory review of India's similar-biologics approval history. It is exactly the scenario where correct name-plus-batch dispensing records matter most, since a hospital may reasonably stock two or three differently branded biosimilars of one reference molecule at once.
Why does batch-level naming and tracking matter for hospital dispensing?
When a hospital pharmacy dispenses a biosimilar, recording the specific brand name and batch number, not just "trastuzumab" or "rituximab" generically, is what allows any later adverse event or efficacy signal to be traced back to the correct manufacturer and lot. This is a meaningfully different documentation standard than dispensing a standard small-molecule generic, where batch-level traceability matters less clinically.
A pharmacy that logs biosimilar dispensing only by INN, without brand and batch detail, loses this traceability entirely, which becomes a real problem if a national or global pharmacovigilance signal later needs to be matched against a specific hospital's dispensing history.
Does switching between differently branded biosimilars of the same molecule raise naming-related risk?
The naming and batch-tracking system exists specifically to manage this scenario safely: switching a patient between two biosimilar brands of the same reference molecule, or between a biosimilar and its originator, is a documented clinical practice in many settings, provided the switch itself is recorded accurately against the correct brand and batch at every dispensing point.
The risk isn't inherent to switching; it's inherent to poor documentation of which specific product a patient received at which point in their treatment course, which is exactly why the naming convention places such weight on brand-plus-batch identification rather than treating every biosimilar of a given molecule as interchangeable in the pharmacy record.
Why does reliable in-house pharmacy tracking of biosimilar names matter for continuity of care?
A hospital that outsources part of a patient's biosimilar therapy to an external pharmacy risks losing the continuous brand-and-batch dispensing record that safe long-term biologic therapy depends on, particularly for a chronic monoclonal-antibody or insulin biosimilar course spanning many refills. A fragmented record across two pharmacies is a genuine pharmacovigilance gap, not just an administrative inconvenience.
Our prescription leakage guide covers what this kind of fragmented sourcing costs a hospital in both oversight and revenue, and our managed hospital pharmacy services piece covers how a single, reliably stocked in-house pharmacy keeps a patient's full biosimilar dispensing history in one traceable record.
Sources
- 1WHO Biosimilars Access Toolkit: Nomenclature — World Health Organization
- 2'Similar biologics' approved and marketed in India — Generics and Biosimilars Initiative Journal
- 3Central Drugs Standard Control Organisation — Drugs and Cosmetics Act, 1940 and Rules, 1945
- 4National List of Essential Medicines 2022 — Central Drugs Standard Control Organisation
- 5Pradhan Mantri Bhartiya Janaushadhi Pariyojana — Department of Pharmaceuticals, Government of India
This article is for informational purposes and is not a substitute for professional medical advice. Biosimilar selection and switching decisions are clinical decisions for the treating doctor based on the individual patient. Consult a qualified physician before starting or changing any biologic treatment.
FAQ
Frequently asked questions
Because a biosimilar is a complex biological product, not a chemically identical copy the way a small-molecule generic is, regulators require each manufacturer's version to carry its own distinct brand name alongside the shared INN, specifically to preserve batch-level traceability for pharmacovigilance.
A proposed four-letter code intended to give every biosimilar and its reference biologic a globally consistent identifier beyond national brand names, aimed at standardising international pharmacovigilance tracking. WHO has since paused formal rollout of the proposal.
India's current approach relies on the brand name plus INN and batch number for traceability, similar to the European Union's model, rather than a separate qualifier suffix system.
Switching between biosimilar brands of the same reference molecule is documented clinical practice in many settings, provided the switch is accurately recorded by brand name and batch at each dispensing point so the treatment history remains traceable.
Because biosimilars are structurally complex biological products rather than chemically identical copies, any manufacturing-lot-specific safety or efficacy signal needs to be traced back to the exact brand and batch dispensed, which standard small-molecule generics generally do not require to the same degree.
Dr. Rajesh IyerMBBS, MD (Pharmacology)
Clinical Pharmacologist
Dr. Rajesh Iyer is a clinical pharmacologist focusing on drug interactions, adverse-effect profiles, biosimilars, and drug-scheduling regulation in India.